Exploiting tumour hypoxia and overcoming mutant p53 with tirapazamine

British Journal of Cancer

Volumn 77, Issue SUPPL. 4, 1998, Pages 12-14

  Brown, J M ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cisplatin; Cytotoxic potentiation; p53 status; Radiation, tirapazamine; Tumour hypoxia

Indexed keywords

MUTANT PROTEIN; PROTEIN P53; RADIOSENSITIZING AGENT; TIRAPAZAMINE;

CONFERENCE PAPER; DRUG CYTOTOXICITY; HYPOXIA; HYPOXIC CELL; PRIORITY JOURNAL; SOLID TUMOR;

ANTINEOPLASTIC AGENTS; CELL HYPOXIA; CISPLATIN; GENES, P53; HUMANS; MUTATION; NEOPLASMS; TRIAZINES;

EID: 0031809934     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.430     Document Type: Article

References (17)

1. Adam M, Gabalski EC, Oehlert JW, Bloch DA, Brown JM, Elsaid AA, Pinto HA and Terris DJ (1998) Tissue oxygen distribution in head and neck patients. Head Neck (in press)
2. Brown JM (1993) SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours. Br J Cancer 67: 1163-1170
3. Brown JM and Lemmon MJ (1990) Potentiation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumours. Cancer Res 50: 7745-7749
4. Brown JM and Siim BG (1996) Semin Radiat Oncol 1: 22-36
5. Brown JM and Wang LH (1998) Tirapazamine: laboratory data relevant to clinical activity. Anticancer Drug Des (in press)
6. Bush RS, Jenkin RD, Allt WE, Beale FA, Bean H, Dembo AJ and Pringle JF (1978) Definitive evidence for hypoxic cells influencing cure in cancer therapy. Br J Cancer 37 (suppl. 3): 302-306
7. Dorie MJ and Brown JM (1993) Tumor-specific, schedule-dependent interaction between tirapazamine (SR 4233) and cisplatin. Cancer Res 53: 4633-4636
8. Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW and Giaccia AJ (1996) Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours (see comments). Nature 379: 88-91
9. Grau C and Overgaard J (1988) Effect of cancer chemotherapy on the hypoxic fraction of a solid tumor measured using a local tumor control assay. Radiother Oncol 13: 301-309
10. Moulder JE and Rockwell S (1984) Hypoxic fractions of solid tumors: experimental techniques, methods of analysis, and a survey of existing data. Int J Radiat Oncol Biol Phys 10: 695-712
11. Nordsmark M, Overgaard M and Overgaard J (1996) Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 41: 31-40
12. Rodriguez R, Ritter MA, Fowler JF and Kinsella TJ (1994) Kinetics of cell labeling and thymidine replacement after continuous infusion of halogenated pyrimidines in vivo. Int J Radiat Oncol Biol Phys 29: 105-113
13. Rodriguez GI, Valdivieso M, Von Hoff DD, Kraut M, Burris HA, Eckardt JR, Lockwood G, Kennedy H and von Roemeling R (1996) A phase I/II trial of the combination of tirapazamine and cisplatin in patients with non-small cell lung cancer (NSCLC). Am Soc Clin Oncol 15: 382 (abstract)
14. Tannock IF (1968) The relation between cell proliferation and the vascular system in a transplanted mouse mammary tumour. Br J Cancer 22: 258-273
15. Teicher BA, Holden SA, al-Achi A and Herman TS (1990) Classification of antineoplastic treatments by their differential toxicity toward putative oxygenated and hypoxic tumor subpopulations in vivo in the FSallC murine fibrosarcoma. Cancer Res 50: 3339-3344
16. Vaupel P, Kallinowski F and Okunieff P (1989) Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res 49: 6449-6465
17. Vaupel PW (1995) In Tumour Oxygenation, Vaupel PW, Kelleher DK and Gunderoth M. (eds), pp. 219-232. Gustav Fischer: Stuttgart